Trials / Unknown
UnknownNCT03363178
Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults
A Single-arm, Open-label, Single-center, Phase 1 Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) After Intradermal Administration in Healthy Adults
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- 19 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally.
Detailed description
Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally. Tuberculin Skin Test(TST) will be conducted after 84+7 days after IP injection and TST result will be read in 48\~72 hours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC3107 | BCG Vaccine, 0.1mL |
Timeline
- Start date
- 2017-12-14
- Primary completion
- 2018-03-31
- Completion
- 2018-03-31
- First posted
- 2017-12-06
- Last updated
- 2017-12-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03363178. Inclusion in this directory is not an endorsement.